NCT04861194: ERECT

EREctile Function Preservation for Prostate Cancer Radiation Therapy (ERECT)

Recruiting now NA Last updated 5 March 2026

What this trial tests

NA trial testing Neurovascular-sparing in Prostate Cancer in 70 participants. Currently enrolling.

Timeline

14 July 2021

Primary endpoint
10 August 2027

10 August 2027

Quick facts

Lead sponsor	UMC Utrecht
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	70
Start date	14 July 2021
Primary completion	10 August 2027
Estimated completion	10 August 2027
Sites	1 location across Netherlands

Drugs / interventions tested

• Neurovascular-sparing

Conditions studied

• Prostate Cancer — all drugs for Prostate Cancer →
• Erectile Dysfunction Following Radiation Therapy — all drugs for Erectile Dysfunction Following Radiation Therapy →

Sponsor

UMC Utrecht — full company profile →

Who can join

18 and older, male only, with Prostate Cancer or Erectile Dysfunction Following Radiation Therapy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Single-arm phase II trial of 70 men with low- or intermediate-risk prostate cancer receiving magnetic resonance guided adaptive radiotherapy (MRgRT) in 5 fractions of 7.25 Gy, additionally sparing the neurovascular bundles, the internal pudendal arteries, the corpora cavernosa, and the penile bulb for erectile function preservation.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. Adaptive magnetic resonance-guided neurovascular-sparing radiotherapy for preservation of erectile function in prostate cancer patients.
   Teunissen FR, Wortel RC, Hes J, Willigenburg T, et al · · 2021 · cited 20× · PMID 34604553 · DOI 10.1016/j.phro.2021.09.002
2. Review of Current Treatment Intensification Strategies for Prostate Cancer Patients.
   Wasim S, Park J, Nam S, Kim J. · · 2023 · cited 14× · PMID 38067321 · DOI 10.3390/cancers15235615
3. The first patient-reported outcomes from the Utrecht Prostate Cohort (UPC): the first platform facilitating 'trials within cohorts' (TwiCs) for the evaluation of interventions for prostate cancer.
   Teunissen FR, Willigenburg T, Meijer RP, van Melick HHE, et al · · 2022 · cited 11× · PMID 35861861 · DOI 10.1007/s00345-022-04092-2
4. Optimal assessment of quality of life for patients with prostate cancer.
   Briggs LG, Sentana-Lledo D, Lage DE, Trinh QD, et al · · 2022 · cited 7× · PMID 36531831 · DOI 10.1177/17588359221141306
5. MR-Guided Transurethral Ultrasound Ablation (TULSA)-An Emerging Minimally Invasive Treatment Option for Localised Prostate Cancer.
   Fung KFK, Cazzato RL, Tricard T, Marini PDE, et al · · 2024 · cited 6× · PMID 38491163 · DOI 10.1007/s00270-024-03696-y
6. Daily online contouring and re-planning versus translation-only correction in neurovascular-sparing magnetic resonance-guided radiotherapy for localized prostate cancer.
   Teunissen FR, van der Voort van Zyp JRN, de Groot-van Breugel EN, Verkooijen HM, et al · · 2022 · cited 5× · PMID 36148156 · DOI 10.1016/j.phro.2022.09.002
7. Association between dose to specific pelvic substructures and urinary and sexual dysfunction following Single-Dose ablative radiotherapy for prostate Cancer: A post hoc analysis from the ABRUPT trial.
   Arcangeli S, Faccenda V, Ferrario F, Chissotti C, et al · · 2026 · PMID 41732214 · DOI 10.1016/j.ctro.2026.101127
8. Challenges and opportunities to minimize the dose in the neurovascular bundles during prostate radiotherapy.
   Brand VJ, Rossi L, Milder MTW, Froklage FE, et al · · 2025 · PMID 40270948 · DOI 10.1016/j.ctro.2025.100959